Oncology Central

Could a shorter course of treatment provide better outcomes for prostate cancer?

Previous research has demonstrated a daily treatment for 2 months of conventionally fractionated high dose external beam radiation therapy (CRT), decreases prostate cancer recurrence and improves metastasis-free survival. Additional studies have demonstrated that moderate hypo-fractionated radiation therapy (HRT), consisting of daily treatment for 1 month using a larger dose per treatment, provides a similar low risk of recurrence and may even be lower with HRT than CRT.

In this study, the researchers wanted to test the latter hypothesis. To achieve this, the team led by investigators at Brigham and Women’s Hospital (MA, USA) analyzed data from over 5000 men from three randomized studies comparing HRT with CRT in men with prostate cancer. The findings were recently published in European Urology Focus.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.